1351 studies found for:    cancer | bevacizumab
Show Display Options
Rank Status Study
21 Recruiting A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
Conditions: Colorectal Neoplasms;   Neoplasm Metastasis;   Intestinal Neoplasms;   Gastrointestinal Neoplasms;   Digestive System Neoplasms
Interventions: Biological: Bevacizumab;   Drug: CPT-11 (Irinotecan);   Drug: 5-FU Bolus;   Drug: 5-FU Infusion;   Drug: l-LV (dl-LV);   Biological: bevacizumab;   Drug: Capecitabine
22 Completed
Has Results
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Biological: cetuximab;   Drug: gemcitabine hydrochloride;   Biological: bevacizumab;   Drug: erlotinib hydrochloride
23 Completed A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Biological: bevacizumab
24 Active, not recruiting Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: cisplatin;   Drug: etoposide;   Radiation: radiation therapy;   Biological: bevacizumab;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim
25 Active, not recruiting Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Biological: cixutumumab;   Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab
26 Active, not recruiting
Has Results
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Drug: sorafenib tosylate;   Biological: bevacizumab
27 Active, not recruiting First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: trastuzumab;   Drug: paclitaxel;   Drug: carboplatin;   Other: placebo;   Biological: bevacizumab
28 Recruiting Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Drug: RAD001;   Drug: bevacizumab
29 Terminated Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Stage II Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Drug: paclitaxel;   Biological: bevacizumab;   Drug: carboplatin;   Other: laboratory biomarker analysis
30 Completed Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Biological: bevacizumab;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis
31 Active, not recruiting Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: irinotecan hydrochloride;   Drug: sorafenib tosylate;   Biological: bevacizumab;   Drug: leucovorin calcium;   Drug: fluorouracil
32 Completed
Has Results
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
Conditions: Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Gastrointestinal Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: erlotinib hydrochloride;   Biological: bevacizumab
33 Completed Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: bevacizumab;   Drug: vinorelbine tartrate;   Other: laboratory biomarker analysis
34 Recruiting Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer
Conditions: Mucinous Adenocarcinoma of the Rectum;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIA Rectal Cancer;   Stage IIB Rectal Cancer;   Stage IIC Rectal Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Rectal Cancer
Interventions: Biological: bevacizumab;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil;   Other: laboratory biomarker analysis
35 Active, not recruiting Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer;   No Prior Chemotherapy
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Bevacizumab
36 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
37 Active, not recruiting Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Conditions: Cervical Cancer;   Endometrial Cancer;   Ovarian Cancer;   Vaginal Cancer;   Carcinoma of the Vulva
Intervention: Drug: Avastin
38 Recruiting Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: veliparib;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: carboplatin;   Biological: bevacizumab;   Other: laboratory biomarker analysis
39 Terminated Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
Conditions: Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage III Colon Cancer;   Stage III Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: capecitabine;   Biological: bevacizumab;   Drug: fluorouracil;   Other: laboratory biomarker analysis
40 Completed Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Biological: bevacizumab;   Other: placebo;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years